36 C
Vientiane
Monday, April 28, 2025
spot_img
Home Blog Page 133

Health In Tech Announces First Quarter 2025 Financial Results

  • Revenues increased 56% over the first quarter 2024 to $8.0 million, reflecting strong market demand
  • Income before income taxes more than tripled to $0.7 million, up 257% over the first quarter 2024
  • Cash position remained strong at $7.6 million as of March 31, 2025

STUART, Fla., April 15, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced its financial results for the first quarter ended March 31, 2025.

Financial Highlights for the First Quarter of 2025

  • The number of enrolled employees (EEs) billed was 24,307, compared to 20,802 in the same period of 2024.
  • Total revenues were $8.0 million, 56% YoY growth.
  • Income before income tax expense was $0.7 million, 8.5% of revenue, compared to $0.2 million, 3.7% of revenue in the same period of 2024
  • Adjusted EBITDA was $1.2 million, compared to $0.5 million in the same period of 2024
  • Cash and cash equivalents were $7.6 million as of March 31, 2025, compared to $7.8 million as of December 31,2024.
  • Accounts receivable was $2.1 million as of March 31, 2025, with 28 days of AR days, compared to $1.6 million, 29 days of AR days as of December 31, 2024.

“We’re off to a strong start in 2025,” said Tim Johnson, CEO of Health In Tech. “First-quarter revenue grew 56% over the first quarter 2024, and income before income tax reached $0.7 million—8.5% of revenue—marking a 257% increase from the same period last year.”

“Our momentum continues to build post-IPO, validating the strategic initiatives we’ve executed. Innovations in our platform, product development, and market expansion are driving meaningful results and laying the groundwork for long-term growth. These gains reflect the strategic investments we made in 2024, particularly in product and service innovation, IT enhancements, infrastructure, cybersecurity, and internal controls. With these foundations in place, we’re now scaling efficiently and reaching a wider market.”

Tim continued: “Since beginning beta development of our large-group third-party AI-powered underwriting platform in November 2024, we’ve seen strong interest from the market. Even in its early stages, we successfully delivered solutions in Q1 to large employers, including one with over 1,000 employees. We’re on track for a full rollout in Q3, marking a major milestone as we broaden our total addressable market and provide smarter, faster quoting for mid-sized and large employers.”

“As we move forward, we’re accelerating new program development and expanding our broker and TPA network to grow our national footprint. With a robust pipeline and sustained momentum, we expect continued strong growth in Q2 2025. We remain dedicated to delivering exceptional value, innovation, and service as we scale.”

Recent Developments and Business Highlights

  • Partnerships and Collaborations. On March 25, 2025, the Company announced a strategic collaboration with DialCare, a leading provider of telehealth and virtual care solutions. Through this partnership, DialCare’s virtual primary care, therapy, and psychiatry services will be integrated into Health In Tech’s self-funded health plan offerings. Members across the U.S. will gain on-demand access to licensed physicians, therapists and psychiatric providers via phone or video consultations. This collaboration further enhances the Company’s mission to deliver smarter, more accessible healthcare solutions for diverse populations.
  • Appointment of Sanjay Shrestha to Board of Directors. On April 10, 2025, the Company announced the appointment of Sanjay Shrestha to its Board of Directors. Mr. Shrestha brings extensive leadership experience in scaling platform-based businesses and driving growth across the energy and technology sectors. He currently serves as President of Plug Power, having joined the company in 2019 as Chief Strategy Officer. He has played a pivotal role in driving growth and expanding value for both customers and shareholders. As General Manager, he significantly broadened the company’s product portfolio and built out the Energy business to deliver end-to-end solutions—including electrolyzers, liquefiers, and cryogenic systems—while overseeing the development of Plug’s hydrogen production facilities. In addition to his operational expertise, Mr. Shrestha has a strong capital market background, having served as a top-ranked renewables research analyst at Lazard Capital Markets and First Albany Capital. His appointment adds valuable industry and financial expertise to the Board and further strengthens Health In Tech’s strategic vision for long-term growth and market expansion.

Conference Call Details

Health In Tech will host a conference call to discuss the financial results for the first quarter of 2025 on April 14, 2025 at 5:00 p.m. (ET). To participate in our live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).

A live audio webcast will be available via the Investor Relations page of Health In Tech’s website at https://healthintech.com/. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Non-GAAP Financial Information

This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.

Use of ForwardLooking Statements

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.

About Health In Tech 

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

 

 

Health In Tech, Inc.

Consolidated Statements of Operations

(Unaudited

Three Months Ended March 31,

2025

2024

Revenues

Revenues from underwriting modeling (ICE)

$2,351,984

$1,784,635

Revenues from fees

5,663,000

3,340,296

    SMR

5,663,000

2,532,922

    HI Card

807,374

Total revenues

8,014,984

5,124,931

Cost of revenues

2,659,585

989,911

Gross profit

5,355,399

4,135,020

Operating expenses

Sales and marketing expenses

1,090,255

1,043,208

General and administrative expenses

3,246,765

1,999,194

Research and development expenses

537,721

760,196

Total operating expenses

4,874,741

3,802,598

Other income (expense):

Interest income

85,366

24,312

Interest expenses

(165,000)

Other income

118,399

Total other income (expense), net

203,765

(140,688)

Income before income tax expense

$684,423

$191,734

Provision for income taxes

(185,831)

(91,198)

Net income

$498,592

$100,536

Net income per share

Basic

$0.01

Diluted

$0.01

 Weighted average common stocks outstanding

Basic

54,619,858

51,769,358

Diluted

56,996,936

51,769,358

 

 

Health In Tech, Inc.

Consolidated Balance Sheets

(Unaudited

March 31, 2025

December 31, 2024

Assets               

Current assets

Cash and cash equivalents

$7,575,037

$7,849,248

  Accounts receivable, net

2,110,601

1,647,103

  Other receivables

3,989,788

500,252

  Deferred offering costs

91,500

  Prepaid expenses and other current assets

1,804,912

787,161

Total current assets

15,571,838

10,783,764

Non-current assets

  Software

4,736,093

3,962,461

  Loans receivable, net

831,994

815,995

  Operating lease – right of use assets

190,275

206,269

Total non-current assets

5,758,362

4,984,725

Total assets

$21,330,200

$15,768,489

Liabilities and stockholders’ equity

Current liabilities

Accounts payable and accrued expenses

$5,478,888

$1,858,840

Income taxes payable

425,556

205,253

Operating lease liabilities – current

69,122

66,881

Other current liabilities

780,045

Total current liabilities

6,753,611

2,130,974

Non-current liabilities

Deferred tax liabilities

294,203

328,676

Operating lease liabilities – non-current

121,595

139,811

Total non-current liabilities

415,798

468,487

Total liabilities

7,169,409

2,599,461

Stockholders’ equity

Common stock, $0.001 par value; Class A Common stock
   150,000,000 shares authorized, 42,973,204 and
   42,914,870 shares issued and outstanding as of
   March 31, 2025 and December 31, 2024, respectively

42,973

42,915

Common stock, $0.001 par value; Class B Common stock
   50,000,000 shares authorized, 11,700,000 shares
   issued and outstanding as of March 31, 2025 and
   December 31, 2024, respectively

11,700

11,700

Additional paid-in capital

9,666,130

9,173,017

Retained earnings

4,439,988

3,941,396

Total stockholders’ equity

14,160,791

13,169,028

Total liabilities and stockholders’ equity

$ 21,330,200

$15,768,489

 

 

Health In Tech, Inc.

Consolidated Statements of Cash Flows

(Unaudited

Three Months Ended March 31,

2025

2024

CASH FLOWS FROM OPERATING ACTIVITIES: 

Net income

$498,592

$100,536

Adjustments to reconcile net income to net cash provided by
(used in) operating activities:

  Amortization expense

135,983

134,787

Provision for potential revenue reduction

780,045

Deferred tax benefits

(34,473)

(60,070)

Amortization of debt discount

165,000

Interest income

(15,999)

(15,999)

Stock-based compensation expense

493,171

Changes in operating assets and liabilities:

Accounts receivable

(463,498)

221,102

Other receivables

(3,489,536)

237,093

Prepaid expenses and other current assets

(1,017,751)

(89,988)

Operating lease right of use assets and liabilities, net

19

624

Accounts payable and accrued expenses

3,420,497

(1,485,329)

Income taxes payable

220,303

112,032

Net cash provided by (used in) operating activities

527,353

(680,212)

CASH FLOWS FROM INVESTING ACTIVITIES:

Development of software

(703,475)

(133,394)

Net cash used in investing activities

(703,475)

(133,394)

CASH FLOWS FROM FINANCING ACTIVITIES:

Payments of deferred offering costs

(98,089)

(243,210)

Net cash used in financing activities

(98,089)

(243,210)

Decrease  in cash and cash equivalents

(274,211)

(1,056,816)

Cash and cash equivalents, beginning of year

7,849,248

2,416,350

Cash and cash equivalents, end of year

7,575,037

1,359,534

Supplemental disclosures of cash flow information:

Cash paid for interest

$-

$-

Cash paid for income taxes

$-

$39,235

Summary of noncash investing and financing activities:

Accrued deferred offering costs included in accounts
   payable and accrued expenses

$33,250

$110,044

Accrued development of software included in accounts
   payable and accrued expenses

$256,140

$9,500

 

Components of Operating Results

Revenues

While our revenue this quarter primarily comes from underwriting activities and program fees associated with customized healthcare plans for small businesses, our growth is driven by delivering solutions that streamline sales processes, enhance service delivery, and shorten the sales cycle for TPAs, MGUs, and brokers. We offer our services through our three subsidiaries. Program services provided by SMR and MGU activities provided by ICE (including eDIYBS) are interdependent, as they cannot function effectively without being combined. Services provided by HI Card is an optional add-on to our other services, and it cannot be offered on a standalone basis. Brokers that utilize the program services on behalf of the small employer provided by SMR and MGU activities provided by ICE, are not obligated to utilize our HI Card service. Currently ICE does not offer underwriting services as a standalone service. In the future, we may consider offering it as a standalone service.

Cost of revenues

Cost of revenues primarily consists of infrastructure costs to operate our platform such as hosting fees and fees paid to various third-party partners for access to their technology, services and amortization expenses of our capitalized internal-use software related to our platform. We mainly outsource captive management services and data services from the third-party companies. Our internal proprietary system seeks to consistently improve underwriting and services results through machine learning and data feeds. The captive management activities include introducing new carriers, conducting due diligence on carriers, conducting feasibility studies to determine the viability to be a stop-loss carrier on the platform, negotiating terms and contracts, coordinating audit requests, managing relationship with unrelated carriers and their regulators and auditor firms to ensure that our risk associated with our service offerings is minimized.

Sales and marketing expenses

Sales and marketing expenses primarily consist of personnel-related costs including salaries, benefits and commissions cost for our sales and marketing personnel. Sales and marketing expenses also include the costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party for sales and customer acquisition.

General and administrative expenses

General and administrative expenses primarily consist of personnel-related costs and related expenses for our executives, finance, legal, human resources, technical support, and administrative personnel as well as the costs associated with professional fees for external legal, accounting and other consulting services, insurance premiums.

Research and development expenses

Research and development expenses primarily consist of personnel-related costs, including salaries and benefits for our research and development personnel. Additional expenses include costs related to the software development, quality assurance, and testing of new technology, and enhancement of our existing platform technology.

Adjusted EBITDA

Adjusted EBITDA represents our earnings from continuing operations before net interest expense, taxes, and depreciation and amortization expense, adjusted to eliminate stock-based compensation expense and public company readiness costs not deemed capitalizable. Adjusted EBITDA is not a measure calculated in accordance with United States Generally Accepted Accounting Principles, or GAAP. We exclude certain non-recurring or non-cash items when calculating Adjusted EBITDA, and we believe this approach provides a more meaningful measure by offering a clearer view of our underlying operational performance.

 

Financial Results Summary

(Unaudited

($ in millions)

Three Months Ended March 31,

2025

2024

% Change

Total revenues

$

8.0

$

5.1

56.4 %

GAAP gross margin

66.8 %

80.7 %

-13.9 %

Income before income tax expense

$

0.7

$

0.2

257.0 %

Adjusted EBITDA

$

1.2

$

0.5

163 %

 

Investor Contact
Investor Relations:
ir@healthintech.com

 

Nature’s Miracle Holding Inc. Announces Up to $2,000,000 Financing

ONTARIO, Calif., April 15, 2025 /PRNewswire/ — Nature’s Miracle Holding Inc. (NMHI) (“Nature’s Miracle” or the “Company”), a leader in vertical farming technology, today announced that on April 11, 2025, that it has successfully arranged financing with Big Lake Capital, LLC (the “Investor”) in the amount of up to $2,000,000 with initial funding of $600,000.  Big Lake Capital, LLC is controlled by Tie “James” Li who is our Chairman and CEO.

Pursuant to the Convertible Promissory Note signed on April 11, 2025, between the Company and Investor, the Investor shall lend to the Company for up to $2,000,000 with the initial tranche of $600,000 which was funded on April 11, 2025. Terms include interest rate of 10% payable monthly and a term of one year. The investor can choose to convert any amount funded plus accrued interest is convertible into shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) at a conversion price equal to $0.198 or 110% of the closing price of the Common Stock on April 11, 2025, the date of initial funding.  As additional consideration, the Investor shall also receive warrants to purchase up to 10,010,101 shares of Common Stock, with an exercise price of $0.198.

About Nature’s Miracle Holding Inc.

Nature’s Miracle (www.Nature-Miracle.com) is a growing agriculture technology company providing products and services to growers in the Controlled Environment Agriculture (“CEA”) industry in the U.S.  The Company’s Common Stock trades on the OTC Markets Group, Inc. (“OTC”) under the symbol “NMHI”.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: the intended use of proceeds from the offering; successful launch and implementation of Nature’s Miracle’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in Nature’s Miracle’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; Nature’s Miracle’s ability to develop and launch new products and services; Nature’s Miracle’s ability to successfully and efficiently integrate future expansion plans and opportunities; Nature’s Miracle’s ability to grow its business in a cost-effective manner; Nature’s Miracle’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of Nature’s Miracle’s business model; developments and projections relating to Nature’s Miracle’s competitors and industry; and Nature’s Miracle’s approach and goals with respect to technology.

These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on the OTC; changes in applicable laws or regulations; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which Nature’s Miracle’s operates; the risk that Nature’s Miracle’s and its current and future collaborators are unable to successfully develop and commercialize Nature’s Miracle’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that Nature’s Miracle’s is unable to secure or protect its intellectual property; the possibility that Nature’s Miracle’s may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in Nature’s Miracle’s filings from time to time with the SEC.

Cision Announces $250 Million New Money Financing, Refinancing, Extension of Debt Maturities

CHICAGO, April 15, 2025 /PRNewswire/ — Cision Ltd. (“Cision“), a leading global provider of earned media software and services to public relations and marketing communications professionals, announced today that it has secured commitments for $250 million of new money financing that will provide additional flexibility for the business and facilitate growth, with overwhelming support from existing lenders and noteholders. Cision’s affiliate Castle US Holding Corporation (the “Company“) entered into a commitment letter and joinders thereto (collectively, the “Commitment Letter“), pursuant to which the Company and holders of over 90% of the Company’s outstanding debt (the “Commitment Parties“) agreed to undertake certain financing transactions, as described below (the “Transactions“). The Commitment Parties include approximately 99% of lenders under the Company’s existing senior secured credit facility and approximately 95% of holders of the Company’s existing unsecured notes (the “Existing Notes“). The Transactions provide material benefits to the Company, including (i) raising approximately $250 million of additional liquidity for the Company, (ii) reducing the principal amount outstanding under certain debt facilities, and (iii) extending debt maturities.

“These Transactions reiterate the support of the high-quality institutions that make up our debt investor base” said Guy Abramo, CEO of Cision. “Having secured additional liquidity and extended our debt maturities to 2030 and beyond, we are positioned to execute on our long-term growth strategy.”

This press release contains important information for remaining holders of the Existing Notes regarding an invitation to participate in the Private Notes Exchange (as defined below). You are encouraged to read this press release in its entirety.

Pursuant to the terms of the Commitment Letter, the Commitment Parties have committed to the following Transactions and related actions: (a) to fund, through a combination of new money and exchange of existing debt of the Company, (i) a senior secured first lien first-out term loan in an aggregate principal amount equal to approximately $250 million of new money, plus transaction fees paid in kind (the “First Out Term Loans“), and (ii) a senior secured first lien second-out term loan in an aggregate principal amount equal to an amount sufficient to facilitate the purchase of term loans under the Existing Credit Agreement (as defined below) at a price agreed between the Company and the Commitment Parties and other lenders participating in the Transactions (the “Second Out Term Loans“), (b) to exchange (the “Private Notes Exchange“) all of their Existing Notes for new first lien third-out 10.00% Senior Secured Notes due 2031 (the “Third Out Notes“), to be issued pursuant to a new indenture, and (c) to provide their consent to amend the existing credit agreement, dated as of January 31, 2020 (the “Existing Credit Agreement“), and the existing indenture governing the unsecured notes, dated as of February 5, 2020 (the “Existing Notes Indenture“), to, among other things, eliminate substantially all restrictive covenants therein and make other modifications to facilitate the Transactions. The Commitment Letter also contemplates that the existing revolving lenders will exchange, on a cashless basis, into a senior secured first lien first-out revolving credit facility in an aggregate commitment amount equal to approximately $137 million (the “First Out Revolver” and, collectively with the First Out Term Loans, the Second Out Term Loans and the Third Out Notes, the “Super Priority Debt“).

The First Out Term Loans and First Out Revolver will have a maturity of April 29, 2030, the Second Out Term Loans will have a maturity of May 31, 2030, and the Third Out Notes will have a maturity of June 30, 2031. The Super Priority Debt will be guaranteed on a senior secured basis, jointly and severally, by the guarantors of the Existing Credit Agreement, and will be secured on a first lien basis by substantially all assets of the Company and such guarantors.  

The Company intends to use debt incurred in the Transactions and the related net proceeds to (i) repay permanently in full and terminate all outstanding commitments under that certain bridge credit agreement, dated as of January 30, 2025, (ii) repay and terminate, or cause the repayment and termination in full of, all outstanding commitments and obligations under certain intercompany credit agreements and promissory notes, (iii) facilitate the purchase of term loans under the Existing Credit Agreement pursuant to the terms of the Transactions, (iv) fund the payment of accrued and unpaid interest on the Existing Notes that have been tendered for cancellation in the Private Notes Exchange and the term loans under the Existing Credit Agreement that are being repurchased in the Transactions and (v) pay related transaction fees and for working capital and general corporate purposes.

“Cision is a leading provider of strategic communications, proactively shaping the future of brands and businesses in real time. The critical liquidity provided by the Transactions positions us to continue to support our 75,000+ partners, including 84% of the Fortune 500, to understand, influence and amplify their stories” said Abramo.

Houlihan Lokey served as financial advisor and Milbank LLP served as legal counsel to Cision. Evercore served as financial advisor and Gibson, Dunn & Crutcher LLP served as legal counsel to the Commitment Parties.

The Private Notes Exchange

The Company expects to issue the Third Out Notes to the noteholders that are Commitment Parties (“Committed Noteholders“) pursuant to the Private Notes Exchange on April 22, 2025 (the “Initial Issuance Date“). Holders of the Existing Notes that are not Committed Noteholders are invited to participate in the Private Notes Exchange on the same terms offered to the Committed Noteholders on or before May 12, 2025, 20 business days after the date hereof. Holders who would like to receive more information about the terms of the Private Notes Exchange should contact Cision at Cision@is.kroll.com. Subject in all respects to Cision’s determination and discretion, and in respect of its right to purchase Existing Notes through open market or privately negotiated transactions:

  • Initial Notes. Holders who contact Cision on or prior to April 17, 2025 may be eligible to receive Third Out Notes on the Initial Issuance Date.
  • Additional Fungible Notes. Holders who contact Cision after April 17, 2025 but on or prior to April 29, 2025 may be eligible to receive Third Out Notes on May 2, 2025 (the “Additional Issuance Date“). The Company expects that Third Out Notes issued on the Additional Issuance Date will be fungible with the Third Out Notes issued on the Initial Issuance Date.
  • Additional Non-Fungible Notes. Holders who contact Cision after April 29, 2025 may be eligible to receive Third Out Notes thereafter. However, Third Out Notes issued after May 2, 2025 may not be fungible with Third Out Notes issued on the Initial Issuance Date or the Additional Issuance Date.

The Committed Noteholders, who collectively own approximately 95% of the Existing Notes, have committed to exchange all of their Existing Notes for Third Out Notes. Due to the high levels of committed participation, holders of Existing Notes are cautioned that the Private Notes Exchange may have adverse effects on the liquidity and market price of Existing Notes that are not tendered and accepted pursuant to Private Notes Exchange.

In addition, Existing Notes that are not tendered and accepted pursuant to the Private Notes Exchange will remain outstanding and will be subject to the terms of the Existing Notes Indenture, as amended to, among other things, eliminate substantially all restrictive covenants therein (the “Proposed Amendments“). Holders are cautioned that, if the Proposed Amendments become operative, the elimination or modification of the covenants and other provisions in the Existing Notes Indenture contemplated by the Proposed Amendments will permit the Company and its subsidiaries to take certain actions previously prohibited by the Existing Notes Indenture that could increase the credit risks with respect to the Company, as well as adversely affect the liquidity, market price and price volatility of the Existing Notes or otherwise be adverse to the interests of holders.

The Third Out Notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act“), or any other securities laws, and the Third Out Notes cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

This press release is for informational purposes only. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. Holders of the Existing Notes are encouraged to consult their own legal, financial and tax advisers regarding the Private Notes Exchange. 

About Cision

Cision is a global leader in consumer and media intelligence, engagement, and communication solutions. We equip PR and corporate communications, marketing, and social media professionals with the tools they need to excel in today’s data-driven world. Our deep expertise, exclusive data partnerships, and award-winning products – including CisionOneBrandwatch, and PR Newswire – enable over 75,000 companies and organizations, including 84% of the Fortune 500, to see and be seen, understand and be understood by the audiences that matter most.

For media inquiries, please contact:
Cision Public Relations
CisionPR@cision.com

Forward-Looking Statements

This press release contains statements that relate to future events and expectations and, as such, constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These forward-looking statements are not historical facts, but only predictions and generally may be characterized by terminology such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “forecast,” “outlook,” “target,” “endeavor,” “seek,” “predict,” “intend,” “strategy,” “plan,” “may,” “could,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements that address activities, events or developments that the Cision or the Company intends, expects, projects, believes or anticipates will or may occur in the future.

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those currently anticipated. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties, many of which will be important in determining the actual future results of Cision, the Company and their subsidiaries and affiliates. These statements are based on current expectations and the current economic environment, and involve a number of risks and uncertainties that are difficult to predict. Actual results could differ materially from those expressed or implied in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date of this press release, and the Company does not undertake any obligation to publicly correct or update any forward-looking statement if the Company later becomes aware that such statement is not likely to be achieved.

 

BRI Prepares Rp3 Trillion for Share Buyback to Sustain Long-Term Performance

JAKARTA, Indonesia, April 14, 2025 /PRNewswire/ — PT Bank Rakyat Indonesia (Persero) Tbk. (BRI) (IDX: BBRI) is carrying out a share buyback as a strategic step to support the employee and corporate share ownership program in relation to the sustainability of BRI’s long-term performance.

BRImo, a financial super app, enables customers to perform various transactions, from online onboarding, payments, purchases, and investments to insurance and financial tracking
BRImo, a financial super app, enables customers to perform various transactions, from online onboarding, payments, purchases, and investments to insurance and financial tracking

Corporate Secretary of BRI, Agustya Hendy Bernadi, stated that the BRI buyback had received approval from the Annual General Meeting of Shareholders (AGMS) held on March 24, 2025, with a maximum amount of Rp3 trillion.

“The buyback will be done through or outside the Stock Exchange, either in stages or all at once, and must be completed no later than 12 (twelve) months after the date of the AGMS,” explained Hendy.

As an initial stage, BRI will conduct the first period of buyback in April 2025 as part of the company’s strategy to enhance investor confidence. The step taken by BRI also considers global and domestic macroeconomic conditions, including the effects of new tariff policies announced by the US President’s administration and uncertainty over the direction of the benchmark rate policy, namely the Federal Funds Rate (FFR).

Hendy added that the decision for the buyback during this period reflects BRI’s strong commitment to safeguarding shareholder interests amid market fluctuations. Furthermore, BBRI’s buyback is also carried out in accordance with applicable regulations, including Article 43 of the Financial Services Authority Regulation (POJK) No. 29 of 2023.

“Through this corporate action, the company has carefully considered current liquidity conditions and financial position, ensuring that the buyback implementation will not disrupt BRI’s financial health,” he stated.

BRI has been conducting buybacks as part of the Employee, and/or Board of Directors and Board of Commissioners Share Ownership Program since 2015. This program is part of the company’s efforts to encourage employee engagement toward the sustainability of the company’s long-term performance improvement.

“BBRI’s buyback is projected to increase the motivation and performance of BRILiaN personnel, enabling optimal achievement of targets and ultimately leading to improved company performance. On the other hand, the implementation of this policy continues to refer to applicable regulations and good corporate governance (GCG) principles,” said Hendy.

For more information about BANK BRI, visit www.bri.co.id

 

 

Covation Biomaterials Announces Launch of BioPTMEG at Chinaplas 2025

SHENZHEN, China, April 14, 2025 /PRNewswire/ — Covation Biomaterials LLC (“CovationBio®“), a biomaterials company with advanced technology in the bio-based materials industry, proudly announces its newest innovation, CovationBio® bioPTMEG, the advanced, sustainable polytetramethylene ether glycol (PTMEG), delivering high performance with significantly lower environmental impact.

BioPTMEG is a bio-based alternative to petroleum-based PTMEG, helping customers reduce their reliance on non-renewable materials and maintain the durability and resilience expected in high performance applications such as spandex, polyurethanes and thermoplastic elastomers.

A few of the superior sustainability benefits offered by CovationBio® bioPTMEG include: 

  • a substantial reduction of greenhouse gas emissions compared to fossil-based incumbents;
  • a product that is 100% bio-based and obtained from annually renewable resources;
  • the use of feedstock such as corncobs which do not compete with primary food sources;
  • a reduced reliance on non-renewable fossil fuel use.
  • Drop-in performance to allow downstream to switch to bio-based raw material without major process change

Mr. Feifeng You, Chairman of CovationBio, stated: “As a force of nature, CovationBio’s vision is to build a sustainable, decarbonized materials industry. To this end, we’re proud to launch CovationBio® bioPTMEG. It uses carbon absorbed by plants from the atmosphere for material creation, improving the quality of life. We’re scaling up production to cut carbon footprints. This is our responsibility to future generations. Through continuous innovation and cooperation, we aim to build a sustainable and regenerative materials industry. We invite all stakeholders to join us in creating a greener, cleaner, and more prosperous world.”

“This drop-in replacement can be seamlessly integrated into existing manufacturing processes and does not require extensive, or even any, product development,” he added

The construction of a plant in Jiangsu Province, Qidong is expected to be mechanically complete toward the end of 2025. Commercial production should begin in the first quarter of 2026.

Those attending Chinaplas may visit the CovationBio® booth at Hall 20, Booth H21 from April 15-18, 2025.
Aligned with this year’s theme, “Transformation, Collaboration, Sustainability,” the team will highlight how CovationBio® bioPTMEG can integrate into customer materials and advance sustainability strategies.

On April 14th 2025, the Global Marketing Director for C4 Platform Dr. Mosha Zhao and the Global Technology Director of CovationBio Dr. Dan Slanac will make the first official introduction to CovationBio® bioPTMEG on the Media Day of Chinaplas 2025 to share the global sustainability commitment of CovationBio and the impact of this new technology. For those interested in learning more, please visit bioPTMEG@covationbio.com.

Disclaimer: The statements regarding product‘s life cycle analysis (LCA) and product performances above are based on tests by CovationBio and True North, an authoritative third party in the US. As the relevant data involves trade secrets, it will only be provided upon legal request in administrative or judicial proceedings. We appreciate your understanding.

About CovationBio®

Founded in 2022, in Newark, Delaware, Covation Biomaterials LLC is a biomaterials company with advanced technology in the bio-based materials industry, offering a product portfolio of high-performance, sustainable solutions.

The company builds on its rich DuPont legacy of groundbreaking scientific innovation and continues to deliver novel solutions at scale across multiple industries, including apparel, carpeting, cosmetics, food, and packaging. Through product lines such as Sorona®, Susterra® and Zemea®, the mission of Covation Biomaterials is to deliver building blocks that will enable customers to provide bio-based products accessible to everyone. Covation, Covation Biomaterials, Sorona, Susterra, and Zemea are trademarks of Covation Biomaterials™ or its affiliates. For more information about Covation Biomaterials, please visit CovationBio.com and follow on WeChat, LinkedIn, Instagram, and Facebook.

2023 VinFuture Special Prize Laureate Prof. Daniel Drucker: Ample room remains for innovation in GLP-1 therapies


HANOI, VIETNAM – Media OutReach Neswire – 14 April 2025 – Together with world-renowned scientists including Prof. Joel F. Habener, Prof. Jens Juul Holst and Assoc. Prof. Svetlana Mojsov, Prof. Daniel Drucker at the University of Toronto and the Lunenfeld-Tanenbaum Research Institute, has discovered the role of glucagon-like peptide-1 (GLP-1), leading to life-changing therapies for people with diabetes and obesity while stimulating emerging applications for neurodegenerative diseases. This groundbreaking innovation has garnered significant recognition for him and the GLP-1 research group, exemplified by the prestigious 2023 VinFuture Special Prize for Innovators with Outstanding Achievements in Emerging Fields, and the 2025 Breakthrough Prize in Life Sciences, awarded earlier this April.

Prof. Daniel Drucker, 2023 VinFuture Special Prize Laureate for Innovators with Outstanding Achievements in Emerging Fields, continues to receive recognition with the 2025 Breakthrough Prize in Life Sciences
Prof. Daniel Drucker, 2023 VinFuture Special Prize Laureate for Innovators with Outstanding Achievements in Emerging Fields, continues to receive recognition with the 2025 Breakthrough Prize in Life Sciences

In this interview, he reflects on the impact and influences of the VinFuture Prize on his further research, as well as the challenges and prospects of expanding GLP-1 accessibility. As global scientific recognition continues to evolve, he shares insights into the vital role of initiatives like the VinFuture Prize in inspiring the next generation of scientists.

VinFuture: Recognizing transformative science

The 2023 VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and honor the scientists behind the discovery of the role of GLP-1. Following the VinFuture Prize, the GLP-1 research group has continuously received recognitions with numerous other prestigious accolades, including their listing among the 2024 Time 100 Most Influential People.

Reflecting on this, Prof. Drucker expressed deep appreciation, noting that these awards provide invaluable support in pushing the boundaries of scientific discovery.

As the VinFuture Prize gains prominence, having GLP-1 science acknowledged as a recipient also helps elevate the global understanding of how it can transform healthcare,” he emphasized.

Continuing its commitment to recognizing impactful advancements, the 2024 VinFuture Prize honored innovators in the biomedical field for their development of CAR T-cell therapy for cancer and other diseases. According to Prof. Drucker, this innovation stands as “a remarkable example of how immunological science can revolutionize the treatment of many cancer types.”

With the honoring of AI and CAR T cell therapy, the trends I observe are consistent with other international awards, where similar innovative themes are celebrated around the same time or within a few years. This alignment reinforces the importance of these breakthroughs.” Prof. Drucker commented.

Among the youngest international science-technology awards, now in its fifth year, the VinFuture Prize is steadily establishing its significance and reputation, evidenced by the increasing number of laureates continuing to receive recognition from prestigious international awards, most notably the Nobel Prize. Prominent examples include Dr. Katalin Karikó and Prof. Drew Weissman (Laureates of the 2021 VinFuture Grand Prize and 2023 Nobel Prize in Physiology or Medicine), Dr. Demis Hassabis and Dr. John Jumper (Laureates of the 2022 VinFuture Special Prize and 2024 Nobel Prize in Chemistry), and Prof. Geoffrey Hinton (Laureate of the 2024 VinFuture Grand Prize and 2024 Nobel Prize in Physics).

Despite being a relatively new award, the VinFuture Prize has done an exceptional job of highlighting high-quality science. The recognition of AI, coinciding with its recent recognition by the Nobel Prize, highlights its transformative impact on numerous aspects of society,” Prof. Drucker said. “So I think the VinFuture Prize council really has its finger on the leading edge of science in many areas.”

Beyond diabetes

2024 was a landmark year for GLP-1 research, with several exciting clinical trials demonstrating benefits extending far beyond obesity to include the treatment of patients with heart disease, obstructive sleep apnea, and knee osteoarthritis. Additionally, Prof. Drucker hinted at early promising results for patients with metabolic liver disease and noted ongoing studies exploring GLP-1’s effects on Alzheimer’s disease, with results expected soon.

The continuous wave of new findings will provide deeper insights into the full potential of GLP-1-based therapies.” Prof. Drucker commented, stating that each study will contribute to refining our understanding of this science.

Furthermore, Prof. Drucker highlighted GLP-1’s neurological effects and its potential clinical application in addressing mental health conditions, including anxiety, depression, and compulsive behaviors. He noted that preliminary, early-stage trials with small patient groups investigating GLP-1’s potential in reducing cravings and treating addiction-related disorders have yielded promising initial results.

Several academic research centers are actively studying GLP-1’s effects on substance use disorders, and major pharmaceutical companies such as Eli Lilly and Novo Nordisk have begun clinical trials to explore these applications further.” Prof. Drucker shared, “It will likely take 12 to 18 months before we gain a clearer picture of whether these medicines can be clinically effective in helping individuals reduce or quit substance use.”

Prof. Drucker also highlighted compelling research indicating GLP-1’s interaction with the brain, extends beyond appetite regulation, suggesting a range of potential therapeutic applications.

Ongoing trials are underway in people with substance use disorders, including alcohol, nicotine, cannabinoids, and opioids, conditions for which existing medicines are not always very effective.” He elaborated, “We have trials underway for Alzheimer’s disease with oral semaglutide, which are expected to conclude by the end of 2025. These investigations will significantly enhance our understanding of GLP-1’s neurological impact and potential clinical applications.

Overcome barriers to maximize impact

Despite the global excitement for the “Ozempic era”, there are many challenges hindering the widespread impact for GLP-1 medicines. These include the current high cost and limited accessibility of the treatments, the reliance on primarily two main drug options (semaglutide and tirzepatide), and the practical limitations of refrigeration and pen-based delivery for most formulations, as Prof. Drucker pointed out.

A key priority is the democratization of these treatments so that everyone who could benefit from them has access. To achieve this, we are working on small-molecule pills that are easier to manufacture and should be more affordable.” He explained.

Prof. Drucker anticipated that increased competition in the GLP-1 market will lead to lower prices, development of newer versions that are easier to use, including once-monthly injections, thereby improving accessibility and convenience for millions worldwide.

Most initial launches have occurred in countries with well-established healthcare and reimbursement systems. Only now are we seeing manufacturing capacity expand enough to increase availability, but costs remain a significant barrier.” He stated, emphasizing the critical need to advance these medicines not only to enhance their efficacy in areas like weight loss and cardiovascular health but also to make them more convenient to take, more affordable, and more broadly accessible to patients globally.

Another major challenge that Prof. Drucker identified is determining the appropriate dosage for extending the therapeutic applications of GLP-1 to conditions beyond diabetes and obesity. While the dosage effective for weight loss may not be suitable for other disorders like Parkinson’s, Alzheimer’s, alcohol use disorder, anxiety, or depression, understanding the dose-response relationship for these conditions requires time and further investigation.

Additionally, research is underway to reduce adverse effects, making GLP-1 treatments safer and more comfortable for patients. Prof. Drucker elaborated, “One key strategy is starting patients on very low doses and gradually increasing them to minimize side effects. Additionally, some companies are researching ways to reduce further adverse effects, such as developing co-formulated anti-nausea compounds to improve tolerability.”

Future research for GLP-1 therapies presents numerous possibilities; however, the translation from research to clinical application for neurodegenerative and substance use disorder treatments still presents unmet needs with a lack of evidence for progress. According to Prof. Drucker, with clinical trials underway, they may yield valuable insights within the next 12 to 24 months regarding the potential extension of GLP-1 therapy benefits from glucose control to complex disorders of the central nervous system.

He identified, “The key lies in understanding how to effectively engage the brain, identifying which regions can respond to GLP-1 signaling, and how to optimize that communication.”

In conclusion, Prof. Drucker highlighted the promising contemporary landscape of scientific research, emphasizing the crucial need to inspire the next generation to embrace science and pursue research careers. In this context, the 2023 VinFuture Special Prize Laureate commended the VinFuture Prize for its valuable contribution in motivating individuals within the scientific community and engaging younger generations in science.

When we visited Vietnam, we met with many young scientists, and I was impressed by VinFuture’s strong efforts to inspire and connect with them. I encourage VinFuture to continue and expand these efforts because investing in young talent is the key to a future filled with groundbreaking innovations.” He stated.

Hashtag: #VinFuture

The issuer is solely responsible for the content of this announcement.

VinFuture

The VinFuture Foundation, established on International Human Solidarity Day on December 20th, 2020, is a non-profit organization co-founded by billionaire Mr. Pham Nhat Vuong and his wife, Mrs. Pham Thu Huong. The Foundation’s core activity is awarding the annual VinFuture Prize, which recognizes transformative scientific and technological innovations capable of making significant positive changes in the lives of millions of people worldwide.

The nomination period for the 2025 VinFuture Prize will close at 2:00 PM on April 17, 2025 (Vietnam time, GMT+7). Submit your nominations here: . Outstanding nominators will be honored through the VinFuture Nominator Recognition Program.The VinFuture Prize consists of four prestigious awards presented each year. The most esteemed is the VinFuture Grand Prize, valued at US$3 million, making it one of the largest annual prizes globally. Additionally, there are three Special Prizes, each valued at US$500,000, specifically dedicated to honoring Women Innovators, Innovators from Developing Countries, and Innovators with Outstanding Achievements in Emerging Fields.

LambdaTest Launches HyperExecute MCP Server to Automate Testing Setups with AI

This new AI-native feature transforms test orchestration, making test setup effortless, intelligent, and exceptionally faster.

NOIDA, India and SAN FRANCISCO, April 14, 2025 /PRNewswire/ — LambdaTest, a unified agentic AI and cloud engineering platform, today announced the launch of the HyperExecute MCP Server, a cutting-edge enhancement to its AI-native test orchestration platform, HyperExecute. This new update introduces the Model Context Protocol (MCP), significantly streamlining automated testing workflows and reducing setup time from hours or weeks to mere minutes.

By integrating MCP, HyperExecute enables AI models to interact autonomously with digital tools, enhancing the speed, efficiency, and simplicity of automated test configurations. Developers and QA teams can automatically analyze project structures, generate precise test commands, and create customized YAML configurations without manual effort.

HyperExecute MCP Server further enhances productivity through real-time insights into test executions and effective management of testing workflows, facilitating seamless continuous integration and delivery. To ease onboarding, LambdaTest also integrated Agentic RAG inside the HyperExecute MCP server. If the user needs help at any point, they could just ask the agent which would fetch answers from the HyperExecute docs directly.

“HyperExecute MCP Server represents a significant leap forward for the quality engineering industry,” said Asad Khan, CEO and Co-Founder of LambdaTest. “We’re not only enhancing the speed and accuracy of testing but also fundamentally simplifying workflows so developers can focus more on innovation and less on setup complexities. Our MCP Server isn’t just another testing tool; it’s a paradigm shift. By automating complex configurations through intelligent AI interactions, we’re redefining what’s possible in test automation—making it faster, smarter, and universally accessible,” he added.

With this launch, LambdaTest continues its commitment to simplifying software testing, improving collaboration, and ensuring superior product quality from development through release. HyperExecute is already redefining test automation by executing tests up to 70% faster than traditional grids, and now, with HyperExecute MCP servers, LambdaTest aims to amplify the Developer Experience and Testing efficiency to the next scale.

To experience the benefits of HyperExecute MCP Server, visit: http://lambdatest.com/hyperexecute-mcp-server

About LambdaTest

LambdaTest is an AI-native, omnichannel software quality platform that empowers businesses to accelerate time to market through intelligent, cloud-based test authoring, orchestration, and execution. With over 15,000 customers and 2.3 million+ users across 130+ countries, LambdaTest is the trusted choice for modern software testing.

  • Browser & App Testing Cloud: Enables manual and automated testing of web and mobile apps across 10,000+ browsers, real devices, and OS environments, ensuring cross-platform consistency.
  • HyperExecute: An AI-native test execution and orchestration cloud that runs tests up to 70% faster than traditional grids, offering smart test distribution, automatic retries, real-time logs, and seamless CI/CD integration.
  • KaneAI: The world’s first GenAI-native testing agent, leveraging LLMs for effortless test creation, intelligent automation, and self-evolving test execution. It integrates directly with Jira, Slack, GitHub, and other DevOps tools.

For more information, please visit  https://lambdatest.com

 

3CLogic and ServiceNow Expand Partnership to Unveil AI-Powered Unified Contact Center Solution to Transform Contact Center Operations

3CLogic Unveils Groundbreaking Integration with ServiceNow to Transform Voice-Driven Self-Service, Enhancing Employee and Customer Experience, Boosting Efficiency, and Reducing Operational Costs

ROCKVILLE, Md., April 14, 2025 /PRNewswire/ — 3CLogic, the AI-powered contact center solution provider built for ServiceNow®, and ServiceNow (NYSE: NOW), the AI platform for business transformation, have expanded their successful partnership to deliver a groundbreaking, end-to-end AI-powered solution for both employee and customer experiences. This solution combines ServiceNow Customer Relationship Management (CRM) products with 3CLogic’s next-generation Customer Experience (CX) platform. The result is a unified solution that enables users to streamline self-service and assisted service operations, reduce operational costs, and enhance both agent efficiency and customer satisfaction.

“These AI-powered solutions help businesses struggling with disconnected CRM and CCaaS systems. By embedding native voice controls, intelligent routing, and real-time insights directly into ServiceNow, we’re delivering a seamless, scalable customer contact center experience,” said Terence Chesire, VP of Product Management for CRM and Industry Workflows at ServiceNow. “This unified approach enhances both self-service and agent-assisted interactions—helping to drive efficiency, reduce costs, and improve service quality at every touchpoint. Always with a focus on delivering customers’ requests.”

Transforming Contact Center Operations with AI
In today’s fast-paced business environment, organizations demand more efficient and effective ways to engage with customers and employees. The new solution from ServiceNow and 3CLogic delivers an innovative approach to contact center management with key features designed to increase productivity and enhance service quality.

Single Agent Experience Across All Channels
The latest 3CLogic integration will include the use of ServiceNow’s newest Native Voice Controls directly embedded in the Customer Service Management (CSM) Configurable Workspace, whereby agents will be able to manage voice interactions alongside digital cases from a single platform. The approach will replace the previous floating Computer Telephony Integration (CTI) frame to extend a more streamlined agent experience while delivering immediate context on the caller, relevant data, and actionable guidance—all in one view.

Real-Time Transcription and AI-Powered Insights
3CLogic’s Real-Time Transcription (RTT) will seamlessly integrate into ServiceNow’s configurable agent workspace, allowing agents to focus entirely on customer issues without the need to take notes. With ServiceNow’s AI capabilities, transcriptions can automatically be transformed into summaries and resolution notes, reducing lengthy call wrap-up processes and average handling times. The integration will also provide managers with critical insights into service trends, enabling better decision-making around training and operational improvements.

Unified Routing for Seamless Interactions
3CLogic’s intelligent, channel-agnostic interaction manager will enhance ServiceNow’s routing capabilities by helping ensure that all customer inquiries—whether digital or voice—are routed to the right agent based on ServiceNow context and date. The universal routing solution will help reduce the effort of maintaining duplicate routing rules and agent skills, resulting in fewer misdirected cases, enabling faster response times, and allowing users to lower costs while improving both agent productivity and customer satisfaction.

“Thanks to the integration of 3CLogic and ServiceNow, our caller identification and authorization process is now significantly faster, saving valuable time on every call compared to our previous system. This streamlined approach not only accelerates the call initiation process but also significantly enhances the overall customer experience and operational efficiency,” said Kurt Mosley, VP of Service Support at Flexential. “We are excited about the continued growth of the 3CLogic and ServiceNow partnership and look forward to further integrations that will drive business success, boost productivity for our teams, and strengthen long-term customer loyalty.”

Streamlining Operations and Driving Business Impact
The new AI-powered solution allows for improved agent performance and substantial cost savings by automating processes and optimizing workflows. Businesses can improve first contact resolution rates, reduce customer effort, and resolve cases faster—all key drivers of customer satisfaction. The various enhancements are expected to roll out throughout the year starting this spring.

3CLogic is a ServiceNow certified Technology and Advanced Platform Build partner with offerings available for ServiceNow’s IT Service Management, CRM and Industry Workflows, and HR Service Delivery solutions. The organization will be unveiling its latest set of capabilities at ServiceNow’s annual Knowledge 2025 event this May in Las Vegas. 

For more information, visit 3CLogic.com.

About 3CLogic
3CLogic transforms customer and employee experiences with its patented and award-winning AI-powered cloud contact center solutions purpose-built to enhance today’s leading CRM and Customer Service Management platforms. Globally available and leveraged by the world’s leading brands, its offerings empower enterprise organizations with innovative capabilities, such as intelligent self-service, Generative AI, Conversational AI, agent automation & coaching, and AI-powered sentiment analytics — all designed to lower operational costs, maximize ROI, and deliver better, faster, and more personalized interactions for IT, employee, and customer service. For more information, please visit www.3clogic.com.

About ServiceNow
ServiceNow, the ServiceNow logo, Now, Now Platform, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries.

This release contains “forward‑looking statements” regarding our future plans and performance. Forward‑looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward‑looking statements. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from the results expressed or implied by the forward‑looking statements we make.

Factors that may cause actual results to differ materially from those in any forward‑looking statements include: (i) delays and unexpected difficulties and expenses in executing the partnership or delivering the product capabilities and offerings, (ii) changes in the regulatory landscape related to AI and (iii) uncertainty as to whether sales will justify the investments in the product capabilities and offerings. Further information on factors that could affect ServiceNow’s financial and other results is included in the filings ServiceNow makes with the Securities and Exchange Commission from time to time.

We undertake no obligation, and do not intend, to update these forward‑looking statements.